Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32971005

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Dec
First author
Powles T

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jan;22(1):e5. doi: 10.1016/S1470-2045(20)30734-8.
    note
    Source null
    related pmid
    33387509
    relationship
    Erratum in

Authors and identifiers

  1. name
    Powles T
    type
    Author
  2. name
    van der Heijden MS
    type
    Author
  3. name
    Castellano D
    type
    Author
  4. name
    Galsky MD
    type
    Author
  5. name
    Loriot Y
    type
    Author
  6. name
    Petrylak DP
    type
    Author
  7. name
    Ogawa O
    type
    Author
  8. name
    Park SH
    type
    Author
  9. name
    Lee JL
    type
    Author
  10. name
    De Giorgi U
    type
    Author
  11. name
    Bögemann M
    type
    Author
  12. name
    Bamias A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Powles T
    type
    Author
  2. name
    van der Heijden MS
    type
    Author
  3. name
    Castellano D
    type
    Author
  4. name
    Galsky MD
    type
    Author
  5. name
    Loriot Y
    type
    Author
  6. name
    Petrylak DP
    type
    Author
  7. name
    Ogawa O
    type
    Author
  8. name
    Park SH
    type
    Author
  9. name
    Lee JL
    type
    Author
  10. name
    De Giorgi U
    type
    Author
  11. name
    Bögemann M
    type
    Author
  12. name
    Bamias A
    type
    Author
bibliography ids
  1. nci-bib-0db32d7264dd33e95a94afc9
book metadata
content sha256
c2ce6d3518e915464b81afa9cb6fff15e34b0671b6ad6ad18830aef59b45878a
document type
citation
dois
  1. 10.1016/S1470-2045(20)30541-6
electronic publication date
display
2020 Sep 21
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32971005
immutable id
pubmed:32971005@c2ce6d3518e915464b81afa9cb6fff15e34b0671b6ad6ad18830aef59b45878a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1574-1588
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jan;22(1):e5. doi: 10.1016/S1470-2045(20)30734-8.
    note
    Source null
    related pmid
    33387509
    relationship
    Erratum in
outcomes validated
false
pmid
32971005
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
ba20bff28d947f0ddf23339504229e7874abab4e35b8dfab2a608b8e5049102c
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Dec
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32971005/
title
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

Preserved source evidence · Not medical advice